If statins (HMG-CoA reductase inhibitors) cause myopathy, the risk is very low (strength of recommendation [SOR]: A). There is no direct evidence to answer this question. A pooled analysis of randomized controlled trials found similar myopathy rates in patients taking statins and placebo. However, a large cohort study revealed a very small but statistically significant increased risk of myopathy in patients taking statins (number needed to harm=10,000/year). Case reports suggest a myopathy risk for all statins, including fatal rhabdomyolysis. Risk of myopathy may increase with higher statin doses, certain comorbid states (eg, hypothyroidism, renal insufficiency [especially with diabetes], recent trauma, perioperative periods, advanced age, ...
Objective: The mechanism of statin-related myopathy is unknown, while its prevalence is probably und...
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhib...
Objective:The mechanism of statin-related myopathy is unknown, while its prevalence is probably unde...
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. HMGCoA reduc...
Background: Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular d...
Background: Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular d...
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhib...
Statins are molecules of fungal origin, which inhibit the hydroxymethylglutaryl-CoA (HMG-CoA) reduct...
Objective: To review the epidemiology, clinical features, proposed mechanisms, risk factors, and man...
Aims: Statins are widely used to prevent cardiovascular events, but little is known about the impact...
Statins are commonly used lipid lowering agents which play a pivotal role in reducing cardiovascular...
Statins are considered to be safe, well tolerated and the most efficient drugs for the treatment of ...
Background: Statins inhibit hydroxymethylglutaryl-coenzyme A reductase, decrease plasma low-density ...
The use of statins for cardiovascular disease prevention is clearly supported by clinical evidence. ...
Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ...
Objective: The mechanism of statin-related myopathy is unknown, while its prevalence is probably und...
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhib...
Objective:The mechanism of statin-related myopathy is unknown, while its prevalence is probably unde...
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. HMGCoA reduc...
Background: Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular d...
Background: Statins are widely used lipid-lowering drugs used for the prevention of cardiovascular d...
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhib...
Statins are molecules of fungal origin, which inhibit the hydroxymethylglutaryl-CoA (HMG-CoA) reduct...
Objective: To review the epidemiology, clinical features, proposed mechanisms, risk factors, and man...
Aims: Statins are widely used to prevent cardiovascular events, but little is known about the impact...
Statins are commonly used lipid lowering agents which play a pivotal role in reducing cardiovascular...
Statins are considered to be safe, well tolerated and the most efficient drugs for the treatment of ...
Background: Statins inhibit hydroxymethylglutaryl-coenzyme A reductase, decrease plasma low-density ...
The use of statins for cardiovascular disease prevention is clearly supported by clinical evidence. ...
Emerging data suggest that the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ...
Objective: The mechanism of statin-related myopathy is unknown, while its prevalence is probably und...
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhib...
Objective:The mechanism of statin-related myopathy is unknown, while its prevalence is probably unde...